Rigel Pharma (RIGL) Tops Q2 EPS by 5c

Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $4.01 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• FirstCash to acquire UK pawn operator Ramsdens for £206 million